For the sake of sharheholders, hopefully it passed, because the alternative is delisting and bankruptcy. You can't blame current management for what's happened. Berlin has done a great job controlling costs. At this point, the science is doing the talking and nothing Berlin can do can make the data stronger or force a pharma into being interested in making a monetary investment in the platform.
News 
Market Data 
Discover 
